Pre-made Acapatamab benchmark antibody ( Bispecific scFv, anti-FOLH1/GCPII;CD3E therapeutic antibody, Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Acapatamab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of non-small cell lung cancer (NSCLC).
| Products Name (INN Index) | Pre-Made Acapatamab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody |
|---|---|
| INN Name | Acapatamab |
| Target | FOLH1,CD3E |
| Format | Bispecific scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | Amgen |
| Conditions Approved | NA |
| Conditions Active | Cancers,Prostrate cancer,Metastatic cancer |
| Conditions Discontinued | NA |
| Development Tech | BiTE Technology |
| Previous Name | NA |
| Gm Offical Target Name | FOLH1/GCPII,CD3E |
| Package |
